{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T06:12:23Z","timestamp":1788502343684,"version":"build-2803163510"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Osteoarthritis (OA) is a degenerative musculoskeletal disease of multifactorial origin causing chronic disability, despite numerous treatment options for which there are no predictive biomarkers on the different endotypes. We aimed at defining a peripheral blood (PB) profile potentially predictive of early and sustained response to intra-articular injection of autologous platelet-rich plasma (PRP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A prospective study was conducted on male and female patients aged 40\u201374 years, with Kellgren-Lawrence knee OA grade 2\u20133 candidates to PRP injection. PB was obtained from patients at enrollment prior to PRP injection to assess immune phenotype of PBMCs with multiparametric flow cytometry; serum antioxidant capacity; PBMC expression of molecules involved in inflammatory pathways; serum concentrations of related inflammatory cytokines and chemokines. After one year of follow-up, response was defined based on WOMAC questionnaires and clinical criteria and correlated with the immune profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 109 enrolled patients, 60 had early and sustained response to treatment and 49 were non-responders, irrespective of age, sex, and previous conservative therapy or surgery. Responders had lower oxidative stress and a peculiar profile of inflammatory markers (higher CD40L, Eotaxin 1; G-CSF, GRO\u03b1, MIP3b, and PD-L1; lower TNF\u03b1, PTX3, and PDGF-AA) and immune cell composition (higher circulating CD14\n                      <jats:sup>+<\/jats:sup>\n                      ; higher central memory CD8\n                      <jats:sup>+<\/jats:sup>\n                      , lower effector memory CD4\n                      <jats:sup>+<\/jats:sup>\n                      and terminal effector CD4\n                      <jats:sup>+<\/jats:sup>\n                      and CD8\n                      <jats:sup>+<\/jats:sup>\n                      cells; lower Tregs) in the PB at baseline.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>We describe an immunophenotype associated with early and sustained response to PRP treatment in knee OA and submit that this may be candidate to validation for predicting clinical benefit.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1951258","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:28:30Z","timestamp":1788499710000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Immuno-based profiling of knee osteoarthritis patients identifies baseline characteristics associated with positive response to autologous platelet-rich plasma injection at one-year follow-up"],"prefix":"10.3389","volume":"17","author":[{"given":"Valentina","family":"Granata","sequence":"first","affiliation":[{"name":"Cellular and Humoral Innate Immunity Lab, IRCCS Humanitas Research Hospital","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Tonutti","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University","place":["Milan, Italy"]},{"name":"Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Marrella","sequence":"additional","affiliation":[{"name":"Milan Unit, National Research Council, Institute for Genetic and Biomedical Research (CNR-IRGB)","place":["Milan, Italy"]},{"name":"Immunity &Immunodeficiency Lab, IRCCS Humanitas Research Hospital","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Camisaschi","sequence":"additional","affiliation":[{"name":"Flow Cytometry Core, IRCCS Humanitas Research Hospital","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Puccio","sequence":"additional","affiliation":[{"name":"Milan Unit, National Research Council, Institute for Genetic and Biomedical Research (CNR-IRGB)","place":["Milan, Italy"]},{"name":"Lab of Translational Immunology, IRCCS Humanitas Research Hospital","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiano","family":"Sconza","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation and Functional Recovery, IRCCS Humanitas Research Hospital","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Monferini","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Rani","sequence":"additional","affiliation":[{"name":"Rizzoli-Argenta Orthopedics and Traumatology Unit, Rizzoli Orthopedic Institute","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Filardo","sequence":"additional","affiliation":[{"name":"Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera Italiana","place":["Lugano, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berardo","family":"Di Matteo","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University","place":["Milan, Italy"]},{"name":"Division of Orthopedics, IRCCS Humanitas Research Hospital","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Selmi","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University","place":["Milan, Italy"]},{"name":"Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Morenghi","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University","place":["Milan, Italy"]},{"name":"Biostatistics Unit, IRCCS Humanitas Research Hospital","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Sobacchi","sequence":"additional","affiliation":[{"name":"Milan Unit, National Research Council, Institute for Genetic and Biomedical Research (CNR-IRGB)","place":["Milan, Italy"]},{"name":"Bone Metabolism Unit, Laboratory of Translational Endocrinology & Metabolism, IRCCS Humanitas Research Hospital","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Ceribelli","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University","place":["Milan, Italy"]},{"name":"Rheumatology and Immunology Unit, ASST Spedali Civili","place":["Brescia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(23)00163-7","article-title":"Global, regional, and national burden of osteoarthritis, 1990-2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021","volume":"5","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1833313","article-title":"From mechanical triggering to metabolic-inflammatory driving: a new paradigm of knee osteoarthritis pathogenesis","volume":"17","author":"Yan","year":"2026","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.semarthrit.2015.11.010","article-title":"A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis-from evidence-based medicine to the real-life setting","volume":"45","author":"Bruy\u00e8re","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2015.11.009","article-title":"Efficacy and safety of oral NSAIDs and analgesics in the management of osteoarthritis: evidence from real-life setting trials and surveys","volume":"45","author":"Pelletier","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"B5","article-title":"Treatment of knee osteoarthritis","volume":"98","author":"Lin","year":"2018","journal-title":"Am Fam Physician"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2013.11.012","article-title":"A systematic review of recommendations and guidelines for the management of osteoarthritis: the chronic osteoarthritis management initiative of the U.S. bone and joint initiative","volume":"43","author":"Nelson","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/art.24925","article-title":"Therapeutic trajectory of hyaluronic acid versus corticosteroids in the treatment of knee osteoarthritis: a systematic review and meta-analysis","volume":"61","author":"Bannuru","year":"2009","journal-title":"Arthritis Rheum"},{"key":"B8","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.joca.2007.06.014","article-title":"OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence","volume":"15","author":"Zhang","year":"2007","journal-title":"Osteoarthritis Cartilage"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1177\/19476035231164733","article-title":"Total knee arthroplasty (TKA): when do the risks of TKA overcome the benefits? Double risk of failure in patients up to 65 years old","volume":"14","author":"Perdisa","year":"2023","journal-title":"Cartilage"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.csm.2024.10.009","article-title":"Platelet-based injections for knee osteoarthritis: do they work, are they safe","volume":"44","author":"Chiari Gaggia","year":"2025","journal-title":"Clin Sports Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/ksa.12320","article-title":"Platelet-rich plasma injections for the management of knee osteoarthritis: the ESSKA-ICRS consensus. Recommendations using the RAND\/UCLA appropriateness method for different clinical scenarios","volume":"32","author":"Kon","year":"2024","journal-title":"Knee Surg Sports Traumatol Arthrosc"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/ksa.12077","article-title":"The use of injectable orthobiologics for knee osteoarthritis: a European ESSKA-ORBIT consensus. Part 1-blood-derived products (platelet-rich plasma)","volume":"32","author":"Laver","year":"2024","journal-title":"Knee Surg Sports Traumatol Arthrosc"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1177\/03635465241246524","article-title":"PRP injections for the treatment of knee osteoarthritis: the improvement is clinically significant and influenced by platelet concentration: a meta-analysis of randomized controlled trials","volume":"53","author":"Bensa","year":"2025","journal-title":"Am J Sports Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1177\/0363546520909397","article-title":"Platelet-rich plasma versus hyaluronic acid for knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials","volume":"49","author":"Belk","year":"2021","journal-title":"Am J Sports Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/ksa.70230","article-title":"Safety profile comparison of intra-articular corticosteroids, hyaluronic acid, platelet-rich plasma, and cell-based injections for knee osteoarthritis: a systematic review and meta-analysis by the ESSKA Orthobiologics Initiative","author":"Bensa","year":"2025","journal-title":"Knee Surg Sports Traumatol Arthrosc"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00167-021-06659-9","article-title":"Platelet-rich plasma injections induce disease-modifying effects in the treatment of osteoarthritis in animal models","volume":"29","author":"Boffa","year":"2021","journal-title":"Knee Surg Sports Traumatol Arthrosc"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.reth.2025.10.017","article-title":"The platelet-rich plasma research ecosystem: from mechanistic insights to precision treatment in knee osteoarthritis","volume":"30","author":"Andia","year":"2025","journal-title":"Regener Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.118674","article-title":"Multimodal immune profiling of peripheral blood to predict the response to intra-articular autologous blood-derived orthobiologic treatment in patients with knee osteoarthritis","volume":"192","author":"Tonutti","year":"2025","journal-title":"BioMed Pharmacother"},{"key":"B19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.joca.2013.10.009","article-title":"NASHA hyaluronic acid vs. methylprednisolone for knee osteoarthritis: a prospective, multi-centre, randomized, non-inferiority trial","volume":"22","author":"Leighton","year":"2014","journal-title":"Osteoarthritis Cartilage"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2004.04.010","article-title":"Efficacy and safety of a single intra-articular injection of non-animal stabilized hyaluronic acid (NASHA) in patients with osteoarthritis of the knee","volume":"12","author":"Altman","year":"2004","journal-title":"Osteoarthritis Cartilage"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/9781444315844.ch7","article-title":"OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited","volume":"12","author":"Pham","year":"2004","journal-title":"Osteoarthritis Cartilage"},{"key":"B22","doi-asserted-by":"publisher","first-page":"5102","DOI":"10.1038\/s41467-023-40790-0","article-title":"CRUSTY: a versatile web platform for the rapid analysis and visualization of high-dimensional flow cytometry data","volume":"14","author":"Puccio","year":"2023","journal-title":"Nat Commun"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fragi.2023.1201019","article-title":"The role of WNT and IL-1 signaling in osteoarthritis: therapeutic implications for platelet-rich plasma therapy","volume":"4","author":"Tonutti","year":"2023","journal-title":"Front Aging"},{"key":"B24","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s11926-017-0652-x","article-title":"Platelet-rich plasma for the management of hip and knee osteoarthritis","volume":"19","author":"Bennell","year":"2017","journal-title":"Curr Rheumatol Rep"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1177\/23259671211026242","article-title":"Minimal clinically important difference and patient acceptable symptom state in patients with knee osteoarthritis treated with PRP injection","volume":"9","author":"Boffa","year":"2021","journal-title":"Orthop J Sports Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnesp.2020.05.019","article-title":"The value of serum total oxidant to the antioxidant ratio as a biomarker of knee osteoarthritis","volume":"38","author":"Bagherifard","year":"2020","journal-title":"Clin Nutr ESPEN"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-015-3290-5","article-title":"Evaluation of prolidase activity and oxidative status in patients with knee osteoarthritis: relationships with radiographic severity and clinical parameters","volume":"35","author":"Altay","year":"2015","journal-title":"Rheumatol Int"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1080\/00365513.2017.1354255","article-title":"Metabolic factors and oxidative stress in osteoarthritis: a case-control study","volume":"77","author":"Tootsi","year":"2017","journal-title":"Scand J Clin Lab Invest"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jot.2025.07.003","article-title":"Growth factor independence 1 ameliorates osteoarthritis by inhibiting chondrocyte ferroptosis via inactivation of MAPK signaling pathway","volume":"54","author":"Jin","year":"2025","journal-title":"J Orthop Translat"},{"key":"B30","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/s41420-023-01613-9","article-title":"Lipid peroxidation in osteoarthritis: focusing on 4-hydroxynonenal, malondialdehyde, and ferroptosis","volume":"9","author":"Zhang","year":"2023","journal-title":"Cell Death Discov"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2020.02.006","article-title":"Release kinetic of pro- and anti-inflammatory biomolecules from platelet-rich plasma and functional study on osteoarthritis synovial fibroblasts","volume":"22","author":"Mariani","year":"2020","journal-title":"Cytotherapy"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00712","article-title":"The long pentraxin PTX3 as a link between innate immunity, tissue remodeling, and cancer","volume":"10","author":"Doni","year":"2019","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1186\/s13018-021-02481-8","article-title":"Correction to: The long pentraxin PTX3: a novel serum marker to improve the prediction of osteoporosis and osteoarthritis bonerelated phenotypes","volume":"16","author":"Visconti","year":"2021","journal-title":"J Orthop Surg Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41419-022-04962-y","article-title":"Pentraxin 3 regulated by miR-224-5p modulates macrophage reprogramming and exacerbates osteoarthritis associated synovitis by targeting CD32","volume":"13","author":"Yin","year":"2022","journal-title":"Cell Death Dis"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01484","article-title":"CD40L expression allows CD8","volume":"8","author":"Tay","year":"2017","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12865-023-00547-2","article-title":"CD40 ligand stimulation affects the number and memory phenotypes of human peripheral CD8","volume":"24","author":"Choi","year":"2023","journal-title":"BMC Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v97.7.1920","article-title":"Eotaxin is a natural antagonist for CCR2 and an agonist for CCR5","volume":"97","author":"Ogilvie","year":"2001","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1177\/1947603518764280","article-title":"Synovial fluid eotaxin-1 levels may reflect disease progression in primary knee osteoarthritis among elderly Han Chinese: a cross-sectional study","volume":"10","author":"Li","year":"2019","journal-title":"Cartilage"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.20239","article-title":"Production of the chemokine eotaxin-1 in osteoarthritis and its role in cartilage degradation","volume":"93","author":"Hsu","year":"2004","journal-title":"J Cell Biochem"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2021.155546","article-title":"Extensive cytokine analysis in synovial fluid of osteoarthritis patients","volume":"143","author":"Yang","year":"2021","journal-title":"Cytokine"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1177\/19476035211049562","article-title":"Novel use of intraarticular granulocyte colony stimulating factor (hG-CSF) combined with activated autologous peripheral blood stem cells mobilized with systemic hG-CSF: safe and efficient in early osteoarthritis","volume":"13","author":"Papadopoulos","year":"2021","journal-title":"Cartilage"},{"key":"B42","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13075-026-03742-9","article-title":"Cytokine profiling of molecular endotypes of knee osteoarthritis: insights from the IMI-APPROACH cohort","volume":"28","author":"Hannani","year":"2026","journal-title":"Arthritis Res Ther"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2018.05.009","article-title":"New insights into the natural course of knee osteoarthritis: early regulation of cytokines and growth factors, with emphasis on sex-dependent angiogenesis and tissue remodeling. A pilot study","volume":"26","author":"Kisand","year":"2018","journal-title":"Osteoarthritis Cartilage"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.2147\/btt.s500522","article-title":"Platelet-derived growth factor as biomarker of clinical outcome for autologous platelet concentrate therapy in grade I knee osteoarthritis","volume":"19","author":"Di Tolla","year":"2025","journal-title":"Biologics"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.124040","article-title":"The (-765 G\u2192C) promoter variant of the COX-2\/PTGS2 gene is associated with a lower risk for end-stage hip and knee osteoarthritis","volume":"70","author":"Schneider","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1161\/01.atv.0000030340.80207.c5","article-title":"Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response","volume":"22","author":"Papafili","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"eaan2585","DOI":"10.1126\/scitranslmed.aan2585","article-title":"TGF-\u03b2 type 2 receptor-mediated modulation of the IL-36 family can be therapeutically targeted in osteoarthritis","volume":"11","author":"Li","year":"2019","journal-title":"Sci Transl Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2015.04.002","article-title":"CCL3 serves as a potential plasma biomarker in knee degeneration (osteoarthritis)","volume":"23","author":"Zhao","year":"2015","journal-title":"Osteoarthritis Cartilage"},{"key":"B49","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s41927-020-00122-x","article-title":"Characterization of the interleukin-17 effect on articular cartilage in a translational model: an explorative study","volume":"4","author":"Sinkeviciute","year":"2020","journal-title":"BMC Rheumatol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.115011","article-title":"Complexity of synovial fluid-derived monocyte-macrophage-lineage cells in knee osteoarthritis","volume":"43","author":"Mikulkova","year":"2024","journal-title":"Cell Rep"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111614","article-title":"The response of two polar monocyte subsets to inflammation","volume":"139","author":"Vishnyakova","year":"2021","journal-title":"BioMed Pharmacother"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/art.43437","article-title":"Immunologic profiling suggests an association between Treg cell dysfunction and pain in knee osteoarthritis","volume":"78","author":"Binvignat","year":"2026","journal-title":"Arthritis Rheumatol"},{"key":"B53","article-title":"Altered expression of CD11c and HLA-DR on monocyte subsets in individuals at risk of rheumatoid and psoriatic arthritis","volume-title":"Arthritis Rheumatol","author":"Prajzlerov\u00e1","year":"2025"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.117.309145","article-title":"Human blood monocyte subsets: A new gating strategy defined using cell surface markers identified by mass cytometry","volume":"37","author":"Thomas","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1951258\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:28:32Z","timestamp":1788499712000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1951258\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":54,"alternative-id":["10.3389\/fimmu.2026.1951258"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1951258","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"article-number":"1951258"}}